Follow
Alice Fabbri
Alice Fabbri
Tobacco Control Research Group, Department for Health, University of Bath
Verified email at bath.ac.uk
Title
Cited by
Cited by
Year
The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review
A Fabbri, A Lai, Q Grundy, LA Bero
American journal of public health 108 (11), e9-e16, 2018
2112018
The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures
L Bero, N Chartres, J Diong, A Fabbri, D Ghersi, J Lam, A Lau, ...
Systematic Reviews 7 (1), 242, 2018
1932018
Defining and conceptualising the commercial determinants of health
AB Gilmore, A Fabbri, F Baum, et al
The Lancet, 2023
1582023
Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis
N Chartres, A Fabbri, LA Bero
JAMA Internal Medicine 176 (12), 1769-1777, 2016
932016
Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
MB Fabbri A, Santos A, Mezinska S, Mulinari S
International Journal of Health Policy and Management 7 (6), 504-509, 2018
782018
Industry funding of patient and health consumer organisations: systematic review with meta-analysis
A Fabbri, L Parker, C Colombo, et al.
BMJ 368, 2020
612020
Food industry sponsorship of academic research: investigating commercial bias in the research agenda
A Fabbri, TJ Holland, LA Bero
Public health nutrition 21 (18), 3422-3430, 2018
482018
Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies’ websites
A Fabbri, G Gregoraci, D Tedesco, F Ferretti, F Gilardi, D Iemmi, C Lisi, ...
BMJ open 6 (6), e011124, 2016
482016
Comparative analysis of medicines safety advisories released by Australia, Canada, the United States, and the United Kingdom
LT Perry, A Bhasale, A Fabbri, J Lexchin, L Puil, M Joarder, B Mintzes
JAMA internal medicine 179 (7), 982-984, 2019
312019
A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia
A Fabbri, Q Grundy, B Mintzes, S Swandari, R Moynihan, E Walkom, ...
BMJ open 7 (6), e016701, 2017
302017
Study sponsorship and the nutrition research agenda: analysis of randomized controlled trials included in systematic reviews of nutrition interventions to address obesity
A Fabbri, N Chartres, G Scrinis, LA Bero
Public health nutrition 20 (7), 1306-1313, 2017
302017
Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study
B Mintzes, S Swandari, A Fabbri, Q Grundy, R Moynihan, L Bero
BMJ Open 8 (2), e019027, 2018
272018
Medical donations are not always free: an assessment of compliance of medicine and medical device donations with World Health Organization guidelines (2009–2017)
S McDonald, A Fabbri, L Parker, J Williams, L Bero
International Health, 2019
262019
Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis
A Fabbri, S Swandari, E Lau, A Vitry, B Mintzes
International Journal of Health Services 49 (2), 273-293, 2019
252019
“Asset exchange”—interactions between patient groups and pharmaceutical industry: Australian qualitative study
L Parker, A Fabbri, Q Grundy, B Mintzes, L Bero
BMJ 367, l6694, 2019
212019
The inclusion of nurses in pharmaceutical industry–sponsored events: guess who is also coming to dinner?
Q Grundy, A Fabbri, B Mintzes, S Swandari, L Bero
JAMA Internal Medicine 176 (11), 1718-1720, 2016
182016
Global Media Coverage of the Benefits and Harms of Early Detection Tests
M O’Keeffe, A Barratt, A Fabbri, JR Zadro, GE Ferreira, S Sharma, ...
JAMA Internal Medicine 181 (6), 865-867, 2021
172021
Pharmaceutical industry payments to leaders of professional medical associations in Australia. Focus on cardiovascular disease and diabetes
EA Karanges, N Ting, L Parker, A Fabbri, L Bero
AJGP 49 (3), 151-154, 2020
162020
A Descriptive Analysis of Medicines Safety Advisories issued by National Medicines Regulators in Canada, Australia, the United Kingdom and the United States - 2007 to 2016.
L Perry, A Bhasale, A Fabbri, J Lexchin, L Puil, M Joarder, B Mintzes
Pharmacoepidemiology and Drug Safety, 2020
162020
Media Coverage of the Benefits and Harms of Testing the Healthy: a protocol for a descriptive study
M O'Keeffe, A Barratt, C Maher, J Zadro, A Fabbri, M Jones, R Moynihan
BMJ open 9 (8), e029532, 2019
132019
The system can't perform the operation now. Try again later.
Articles 1–20